熱門資訊> 正文
TuHURA Biosciences和Kineta股东批准拟议交易
2025-06-24 05:19
- TuHURA Biosciences (NASDAQ:HURA) said that its stockholders have approved the proposed merger with Kineta during their special meeting.
- In addition to the merger approval, TuHURA Biosciences announced that its stockholders also approved all proposals presented at the company's special meeting.
- These proposals included increasing the company's authorized shares to 200M and a plan to reincorporate the company in Delaware.
- The parties expect the merger to close as soon as possible after fulfilling or waiving any remaining closing conditions.
More on TuHURA Biosciences
- TuHURA Biosciences: Encountering Serious Cash Issues And A Long Timeline
- Historical earnings data for TuHURA Biosciences
- Financial information for TuHURA Biosciences
推薦文章
一圖看懂 | 淨利潤大幅增長！阿里Q2淨利同比增76%至424億元；閃購業務引流效果顯著
一周財經日曆 | 大小非農數據來襲，能否決定9月降息計劃？蔚來、博通財報壓軸登場
一周IPO丨打新「賺錢效應」爆表！佳鑫國際首日飆漲177%；大行科工、勁方醫藥或即將啟動招股
【A+H】禾賽科技回港上市獲備案 面臨募資與定價雙重考驗
特朗普試圖解僱美聯儲理事庫克，美股為何無動於衷？一文解讀
自動駕駛成負面資產！調查顯示：FSD降低消費者購買特斯拉意願
還能領先多久？從4月美股觸底算起：亞洲科技股持續跑贏納斯達克100
美股機會日報 | 史上最快破萬億，美企正以創紀錄速度回購！績優股走強，Snowflake績后大漲超14%
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
